Orforglipron Vs Wegovy Vs Mounjaro: Do They Work The Same Way? - Guide | Cured Pharmacy

Orforglipron Vs Wegovy Vs Mounjaro: Do They Work The Same Way?

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

Featured Product

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

From £145.00£124.99UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment →✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: 12 June 2026

Last Updated: 12 August 2026

If you have been following the weight loss medication space in 2026, you have likely heard three names come up again and again — Wegovy, Mounjaro, and now the newest arrival, Orforglipron. All three are being talked about as transformative treatments for obesity, but they are not identical, and the differences between them matter enormously depending on your health goals, lifestyle, and medical history.

Quick Summary

Understanding the key differences between these three medications can save you time, money, and frustration. Whether you are considering your first weight loss treatment or thinking about switching, knowing how each drug works helps you and your prescriber make the right call together.

  • Wegovy (semaglutide) is a once-weekly injectable GLP-1 receptor agonist approved for weight management in the UK.
  • Mounjaro (tirzepatide) is a once-weekly injection that targets both GLP-1 and GIP receptors, offering enhanced weight loss in clinical trials.
  • Orforglipron is a once-daily oral GLP-1 receptor agonist — the first pill of its kind — currently progressing through regulatory approval.
  • All three reduce appetite and slow gastric emptying, but their molecular structures, delivery methods, and receptor targets differ significantly.
  • The best option for you depends on your BMI, lifestyle, injection tolerance, and any existing health conditions.

Weight Loss Medication Matcher

Answer three quick questions to see which medication type may suit your lifestyle best. This is for informational purposes only — always consult your prescriber.

1. How do you feel about self-injecting weekly?

This tool is for guidance only. Always speak to a qualified prescriber before starting any medication.

Table of Contents

How Each Drug Works at a Biological Level

To understand whether these three treatments work the same way, you first need to understand what GLP-1 actually is. GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after eating. It signals to your brain that you are full, slows down digestion, and tells the pancreas to produce insulin in response to rising blood glucose. When you mimic or amplify this hormone artificially, the result is reduced appetite, fewer cravings, and steadier blood sugar levels — all of which contribute to meaningful weight loss over time.

Wegovy contains semaglutide, a synthetic molecule that closely mimics natural GLP-1. It binds to GLP-1 receptors throughout the body, particularly in the brain and gut. Crucially, it has been chemically modified to survive degradation in the bloodstream, giving it a half-life long enough to work with just one injection per week. This modification — attaching the molecule to a fatty acid chain — is also what makes semaglutide an injectable rather than an oral treatment, as stomach acid would otherwise destroy it.

Mounjaro contains tirzepatide, which operates on a dual-receptor basis. It targets both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is another gut hormone that plays a role in fat metabolism and insulin sensitivity. By activating both pathways simultaneously, tirzepatide produces a broader hormonal effect — and in clinical trials, it has consistently outperformed single-receptor GLP-1 agonists in terms of total weight reduction. For people exploring weight loss treatments in the UK, Mounjaro represents a genuine step forward.

Orforglipron takes an entirely different structural approach. Rather than being a peptide-based molecule (which requires injection), it is a small-molecule GLP-1 receptor agonist. This means it is chemically compact enough to survive the digestive tract and be absorbed through the gut wall into the bloodstream — making it the first truly effective oral GLP-1 medication. It activates the same GLP-1 receptors as semaglutide, but via a fundamentally different molecular structure, which is why it can be swallowed as a tablet rather than injected.

  • Wegovy = peptide-based GLP-1 agonist, weekly injection
  • Mounjaro = dual GLP-1 and GIP agonist, weekly injection
  • Orforglipron = small-molecule GLP-1 agonist, daily oral tablet
  • All three reduce appetite centrally via the hypothalamus
  • All three slow gastric emptying, prolonging the feeling of fullness

Orforglipron vs Wegovy vs Mounjaro: Do They Work the Same Way? — Key Differences Explained

While all three medications tap into the GLP-1 system, Orforglipron vs Wegovy vs Mounjaro: Do they work the same way? is a question with a nuanced answer. They share a common biological endpoint — reducing appetite and supporting sustainable weight loss — but the route they take to get there is markedly different, and those differences have real-world consequences for patients.

The most obvious difference is the delivery method. Wegovy and Mounjaro both require subcutaneous injections, typically administered in the abdomen, thigh, or upper arm. For many people, this is perfectly manageable, but it does represent a practical barrier — particularly for those with needle phobia, certain disabilities, or unpredictable routines. Orforglipron dissolves this barrier entirely, offering the same class of drug action in a once-daily pill. This is significant not only for patient preference but potentially for global access in regions where cold-chain storage for injectables is difficult to maintain.

Another meaningful difference lies in the receptor targets. Wegovy and Orforglipron are both pure GLP-1 agonists. Mounjaro, by contrast, adds GIP receptor activation to the equation. This dual mechanism is thought to produce a synergistic effect on fat metabolism that neither drug achieves alone. Early evidence suggests that the brain's response to GIP receptor activation may reduce the nausea commonly associated with GLP-1 agonists, which could partly explain why Mounjaro appears better tolerated by some patients despite its potency.

Orforglipron also has important practical advantages in terms of storage. Injectable semaglutide and tirzepatide require refrigeration, which can complicate travel, holidays, and certain living arrangements. As an oral tablet, Orforglipron can be stored at room temperature — a seemingly minor detail that makes a substantial difference to daily life for long-term users.

  • Delivery: tablet (Orforglipron) vs injection (Wegovy and Mounjaro)
  • Receptor targets: GLP-1 only (Wegovy, Orforglipron) vs GLP-1 + GIP (Mounjaro)
  • Dosing frequency: daily (Orforglipron) vs weekly (Wegovy and Mounjaro)
  • Storage: room temperature (Orforglipron) vs refrigerated (Wegovy and Mounjaro)
  • Regulatory status in 2026: Wegovy and Mounjaro approved in UK; Orforglipron under review

Clinical Trial Results and Weight Loss Outcomes

The clinical evidence for all three medications is impressive by any historical standard for obesity treatment. Wegovy's landmark STEP trial programme demonstrated average weight loss of around 14.9% of body weight over 68 weeks in people without diabetes — a result that significantly outperformed older treatments. Since its NHS availability expanded, it has become a cornerstone of UK weight management services. If you are looking into medically supported weight loss programmes, semaglutide remains one of the most rigorously studied options available.

Mounjaro's SURMOUNT trials pushed the bar even higher. Participants on the highest dose (15mg weekly) achieved an average weight loss of approximately 20.9% of body weight — figures that were previously only seen with bariatric surgery. This has made tirzepatide the most effective pharmacological treatment currently available in the UK by weight loss percentage. For people with a BMI above 35 who are seeking maximum results, this dual-receptor mechanism offers something genuinely new.

Orforglipron's Phase 3 ATTAIN-WEIGHT trials (data emerging through 2025 and into 2026) showed participants achieving approximately 7.9% to 9.4% average weight loss over 36 weeks, with ongoing improvements beyond that point. While this figure may appear modest compared to Mounjaro, it is crucial to consider that Orforglipron is an oral pill — and achieving meaningful, sustained weight loss through a tablet rather than an injection would represent a significant shift in how obesity is managed globally, particularly in primary care settings where injectable treatments face practical and psychological barriers.

It is also worth noting that head-to-head trials between these three medications do not yet exist. All comparisons are cross-trial and should be interpreted cautiously, as patient populations, trial designs, and dose escalation protocols differ.

  • Wegovy: ~14.9% average weight loss over 68 weeks (STEP trials)
  • Mounjaro: ~20.9% average weight loss at highest dose (SURMOUNT trials)
  • Orforglipron: ~7.9–9.4% average weight loss over 36 weeks (ATTAIN trials)
  • No direct head-to-head trials between all three yet published
  • Results are dose-dependent and vary based on individual patient factors

Side Effects and Tolerability Compared

All three medications share a broadly similar side effect profile, which reflects their shared GLP-1 mechanism. Nausea is the most commonly reported complaint across all three drugs, particularly during the dose escalation phase. This occurs because slowing gastric emptying — while beneficial for appetite control — can cause discomfort when the stomach is being asked to process food more slowly than it is used to. In most people, nausea is mild to moderate and tends to reduce after the first few weeks as the body adapts.

Vomiting, diarrhoea, constipation, and abdominal discomfort are also reported with all three agents. These effects are generally more pronounced at higher doses and during the initial weeks of treatment. Clinical guidance recommends starting at the lowest dose and titrating upwards gradually — a strategy that substantially improves tolerability for the majority of patients.

Where the medications diverge somewhat is in the severity and pattern of gastrointestinal events at equivalent therapeutic doses. Some clinical data suggests that Mounjaro may produce less severe nausea relative to the weight loss it delivers, potentially due to the GIP receptor component. Orforglipron's GI side effect profile in trials has been comparable to injectable GLP-1 agonists, though being a daily tablet means there is no single-day peak in drug levels as there is with weekly injections, which may smooth out symptom patterns for some users.

Rare but serious side effects to be aware of across all three include potential pancreatitis, gallbladder problems, and — in animal studies though not confirmed in humans — a theoretical concern regarding thyroid C-cell tumours. These risks are reflected in the prescribing guidelines for Wegovy and Mounjaro, and are expected to apply equally to Orforglipron. Anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should avoid all GLP-1 receptor agonists.

  • Common: nausea, vomiting, diarrhoea, constipation (all three drugs)
  • Nausea typically peaks during the first 4–8 weeks and usually improves
  • Slow dose escalation is the single most effective way to reduce side effects
  • Injection site reactions apply only to Wegovy and Mounjaro
  • All three are contraindicated in people with personal or family history of MTC or MEN2

Head-to-Head Comparison Table

Feature Wegovy (Semaglutide) Mounjaro (Tirzepatide) Orforglipron
Drug class GLP-1 receptor agonist Dual GLP-1 / GIP receptor agonist GLP-1 receptor agonist (small molecule)
Administration Weekly subcutaneous injection Weekly subcutaneous injection Once-daily oral tablet
Manufacturer Novo Nordisk Eli Lilly Eli Lilly
UK regulatory status (2026) Approved (MHRA) Approved (MHRA) Under review / awaiting approval
Average weight loss ~14.9% body weight ~20.9% body weight ~7.9–9.4% body weight (36 weeks)
Refrigeration required Yes Yes No (room temperature stable)
Needle-free option No No Yes
Main side effects Nausea, vomiting, diarrhoea Nausea, vomiting, diarrhoea Nausea, vomiting, diarrhoea
Suitable for needle-phobic patients No No Yes
Evidence base maturity Extensive (Phase 3 + real-world) Extensive (Phase 3 + real-world) Growing (Phase 3 trials ongoing)

Which Treatment Is Right for You?

Choosing between these three medications is not simply a matter of picking the one with the highest weight loss numbers. Your prescriber will consider a range of individual factors including your starting BMI, existing medical conditions, current medications, and your ability to self-inject. Each drug has a genuine place in the treatment landscape, and none of them is universally superior for all patients.

Wegovy is an excellent starting point for people who are comfortable with injections and want a clinically well-established, MHRA-approved treatment with a long real-world track record. It is particularly well studied in people without diabetes and has robust cardiovascular outcome data from the SELECT trial showing a reduction in major adverse cardiovascular events. If you want a proven, widely available option with strong NHS prescribing pathways, semaglutide remains highly competitive.

Mounjaro is the strongest option for people seeking maximum weight loss and who are either comfortable with injections or motivated enough to try them. Its dual-receptor mechanism produces results that rival surgical outcomes in some patients. It is also an excellent choice for people with type 2 diabetes, as tirzepatide was originally developed as a diabetes medication and carries proven glucose-lowering benefits alongside its weight loss effects. Many people now accessing weight management support are choosing Mounjaro due to its superior trial results.

Orforglipron is the natural choice for anyone with needle phobia, logistical concerns about injections, or a lifestyle that makes weekly self-injection impractical. It is also likely to be more widely accessible once approved, given that it requires no refrigeration and no injection training. However, as it is still awaiting full regulatory approval in the UK as of 2026, it is not yet available through standard prescribing channels. Watch this space — the approval timeline is advancing, and this medication has the potential to reach patients who have previously been unable or unwilling to use injectable treatments.

  • Choose Wegovy if you want a proven, injectable GLP-1 with extensive safety data and cardiovascular benefits
  • Choose Mounjaro if you want maximum weight loss and are happy with weekly injections
  • Choose Orforglipron once approved if you are needle-phobic or need a pill-based option
  • Discuss all options with a qualified prescriber before making any decision
  • Your BMI, comorbidities, and lifestyle all influence which option is most appropriate for you

Key Takeaways

  • All three medications work through the GLP-1 system to reduce appetite, slow digestion, and promote weight loss — but they differ in structure, delivery, and receptor targets.
  • Mounjaro offers the highest average weight loss due to its dual GLP-1 and GIP receptor mechanism, while Wegovy has the longest real-world track record in the UK.
  • Orforglipron is the only oral option in this class, making it potentially transformative for patients who cannot or will not self-inject.
  • Side effects are broadly similar across all three, with nausea being the most common — slow dose escalation significantly reduces this for most people.
  • Regulatory status matters: as of 2026, Wegovy and Mounjaro are MHRA-approved and available in the UK, while Orforglipron is still progressing through the approval process.

When to Seek Professional Advice

If you are considering any of these medications, the most important first step is a proper medical assessment. These are prescription-only treatments for good reason — they interact with several other medications, they are contraindicated in certain conditions, and they require dose escalation schedules that must be followed correctly to maximise safety and effectiveness.

You should speak to a prescriber urgently if you develop severe abdominal pain (which could indicate pancreatitis), persistent vomiting that prevents you from keeping fluids down, significant changes in vision, or signs of low blood sugar if you are also taking insulin or sulfonylureas. You should also seek advice before starting any of these medications if you have a history of eating disorders, gallbladder disease, kidney disease, or thyroid conditions.

A qualified UK prescriber — such as a prescribing pharmacist or GP — can review your full health history, assess your eligibility, recommend the most appropriate medication, and monitor your progress safely. Do not start, stop, or switch these medications without professional guidance.

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My AssessmentReturning Customer?Log In to Your Account

Scientific References

  1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021. [Accessed 12 August 2026]
  2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. The Lancet, 2022. [Accessed 12 August 2026]
  3. BMJ Analysis: Oral GLP-1 receptor agonists — the next frontier in obesity pharmacotherapy, 2024. [Accessed 12 August 2026]
  4. Tirzepatide for managing overweight and obesity (TA924), NICE Technology Appraisal, 2024 [Accessed 12 August 2026]
  5. Semaglutide for managing overweight and obesity (TA875), NICE Technology Appraisal, 2023 [Accessed 12 August 2026]
  6. Wegovy (semaglutide) 2.4 mg solution for injection – Summary of Product Characteristics, Electronic Medicines Compendium (EMC), 2023 [Accessed 12 August 2026]
  7. Mounjaro (tirzepatide) solution for injection – Summary of Product Characteristics, Electronic Medicines Compendium (EMC), 2023 [Accessed 12 August 2026]
  8. Deanfield J et al., Orforglipron (LY3502970), an oral non-peptide GLP-1 receptor agonist for type 2 diabetes – NEJM phase 2 trial results, The Lancet, 2023 [Accessed 12 August 2026]
  9. Pharmacological Treatment of Type 2 Diabetes – Position Statement, Diabetes UK, 2023 [Accessed 12 August 2026]

Frequently Asked Questions

How long does Orforglipron take to show weight loss results?

Orforglipron typically begins showing measurable weight loss results within four to eight weeks of starting treatment, based on clinical trial data. In the Phase 3 ATTAIN trials, meaningful reductions in body weight were observed over a 36-week period, with results continuing to build the longer treatment was maintained.

Is Orforglipron safe to take if I have needle phobia?

Orforglipron is safe to consider for people with needle phobia because, unlike Wegovy and Mounjaro, it is taken as a once-daily oral tablet rather than an injection. This makes it a genuinely suitable alternative for patients who are unable or unwilling to self-administer subcutaneous injections for weight management.

Can you take Orforglipron with other diabetes medications?

Whether you can take Orforglipron with other diabetes medications depends on the specific medicines involved, and this must always be assessed by a prescriber. Combining GLP-1 receptor agonists with insulin or sulfonylureas may increase hypoglycaemia risk. Always disclose your full medication list before starting any new weight loss treatment.

What is the dose of Orforglipron for weight loss?

The dose of Orforglipron for weight loss in clinical trials started at 3mg once daily and was gradually escalated to a target maintenance dose of 36mg or 45mg daily, depending on tolerability. Dosing is titrated slowly to reduce gastrointestinal side effects such as nausea, which is common when starting GLP-1 receptor agonists.

Back to blog